

A stack of books is shown from a low angle, with the spines of several books visible. The books have various colored covers, including red, orange, and yellow. A semi-transparent gradient overlay in shades of red and orange is applied over the right side of the image. The word "BACILLUS" is written in white, bold, uppercase letters on the red portion of the overlay. Below it, the name "Dr. Tanmay Mehta" is written in a smaller, black, sans-serif font.

BACILLUS

Dr. Tanmay Mehta



Learning objectives

At the end of the session, the students will be able to

- Describe morphology and antigens
- Describe Pathogenesis & Clinical features
- Choose appropriate lab diagnosis and interpret the results
- Describe prevention and treatment



General Features

- Obligate Aerobes
- Gram-positive spore forming bacilli
- Non-bulging spores
- Generally motile with peritrichous flagella & non-capsulated (Except *B.anthraxis*)
- Pathogenic species - *B. anthracis* and *B. cereus*



BACILLUS ANTHRACIS



History

- **1849 - Pollender** - First pathogenic bacterium **seen under microscope**
- Anthrax was the first communicable disease shown to be transmitted by inoculation of infected blood
- **1876 - Robert Koch** - First bacterium to be isolated in **pure culture**
- **Koch's postulates** were based on *B. anthracis*
- **1881 - Louis Pasteur** - Anthrax vaccine was the **first live attenuated bacterial vaccine** prepared



Virulence Factors and Pathogenesis

- **Anthrax Toxin**

1. **Edema factor** - Active fragment

- Acts as adenylyl cyclase → increases host cell cAMP

2. **Protective factor** - Binding fragment. Binds to the host cell receptors and facilitates the entry of other fragments into the host cells.

3. **Lethal factor** - Causes cell death - Acts by cleaving host cell MAPK (mitogen-activated protein kinases).



Virulence Factors and Pathogenesis

- Toxin fragments are **not toxic individually**, but in combination they produce local edema and generalized shock.
- Toxin synthesis is controlled by a plasmid (pX01).
- Loss of plasmid makes the strain avirulent (Basis of original anthrax vaccine prepared by Pasteur)
- **Anthrax Capsule**
 - Polypeptide capsule (polyglutamate)
 - Capsule is plasmid (pX02) coded
 - Inhibits complement mediated phagocytosis



Clinical Manifestations

- **Transmission**

- Cutaneous mode—spores entering through the abraded skin
- Inhalation of spores
- Ingestion of carcasses of animals dying of anthrax containing

- **Clinical Types**

1. Cutaneous anthrax
2. Pulmonary anthrax
3. Intestinal anthrax – rare, occurs due to ingestion of spores

Cutaneous v/s Pulmonary Anthrax

	Cutaneous anthrax	Pulmonary anthrax
Also called as	Hide porter's disease	Wool sorter's disease
Transmission	Cutaneous exposure to spores	Inhalation of spores
Clinical Features	<p><u>Malignant pustule</u></p> <ul style="list-style-type: none"> Begins as a papule → painless vesicle → coal-black, necrotic eschar surrounded by non-pitting indurated edema 	<p><u>Hemorrhagic pneumonia-</u></p> <p>Bacilli spread by lymphatics or blood →</p> <ul style="list-style-type: none"> Bacteremia Hemorrhagic mediastinitis Hemorrhagic meningitis
Prognosis	Self-limiting	Fatal
Bioterrorism	Rarely causes bioterrorism	MC form for bioterrorism

Malignant Pustule





Animal Anthrax

- Anthrax is primarily a **zoonotic disease**
- **Animals affected** – Herbivores -cattle, sheep and less often horses & pigs
- **Acquired** by ingestion of spores present in soil. Direct spread from animal to animal is rare
- **Presentation** - fatal septicemia
- **Infective materials** - Discharges from mouth, nose & rectum. Bacilli sporulate in soil



Epidemiology

- **Animal anthrax:** Progressive global reduction in livestock anthrax due to effective preventive measures
 - **Enzootic (endemic) & Epizootic (epidemic)** forms
 - Prevalent in Andhra-Tamil Nadu border, foci in Karnataka & West Bengal
- **Human anthrax**
- **Incidence** highest in Africa, central & southern Asia.
 1. **Non-industrial** cases – Agricultural exposure to animals
 2. **Industrial cases** - Infected animal products such as hides, hair, bristles and wools.


A background image showing laboratory glassware, including a test tube and a beaker, with a red and orange color scheme.

Laboratory Diagnosis

- High risk of laboratory acquired infection
- **Specimen Collection**
 - Pus or swab from malignant pustule
 - Sputum in pulmonary anthrax
 - Blood (in septicemia)
 - CSF (in hemorrhagic meningitis)
 - Gastric aspirate, feces or food (in intestinal anthrax)
 - Ear lobes from dead animals.

Laboratory Diagnosis...Specimen Microscopy

- **Gram staining**
 - **Gram-positive, large rectangular rods**
 - Spores are usually not seen in clinical samples



Laboratory Diagnosis...Specimen Microscopy

- **McFadyean's reaction**
 - Gurr's polychrome methylene blue - Capsule appears as amorphous purple material surrounding blue bacilli






Laboratory Diagnosis...Specimen Microscopy

- **Direct immunofluorescence test (direct-IF)**
- Capsular and cell wall polypeptide antigens detected
- Useful during bioterrorism outbreaks
- **Ascoli's thermoprecipitation test**
- It is a ring precipitation
- Done when sample is received in putrid form & bacilli are non-viable


CULTURE

- Aerobic, non-fastidious
- Sporulation -25–30°C, distilled water, 2% NaCl, oxalate and oxygen
- **Nutrient agar**
 - Frosted glass
 - Medusa Head Appearance



CULTURE

- **Blood agar** - dry wrinkled, non-hemolytic
- **Gelatin stab agar** - Inverted fir tree appearance
- **Selective media:**
 - Solid medium with penicillin - string of pearl appearance
 - PLET medium (Polymyxin, lysozyme, EDTA and thallos acetate in heart infusion agar)





Culture Smear

- **Gram-staining - Bamboo stick appearance**
- **Spores:**
 - Hot malachite green (Ashby's method)
 - 0.25% sulfuric acid (spores are acid fast)
- **Lipid granules**
 - Sudan black B (Burdon's method).



Molecular Diagnosis

- **PCR with specific primers**
 - BA pX01 (encoding protective Ag)
 - BA pX02 (encoding capsular polysaccharide)
- **Molecular typing** - useful for epidemiological studies
 - MLVA (Multiple locus variable number of tandem repeat analysis)
 - AFLP (Amplified fragment length polymorphisms).



TREATMENT

- **Antibiotic regimen for treatment**
 - **Ciprofloxacin/doxycycline** + clindamycin, and/or rifampin- 60 days
- **Antibiotics for postexposure prophylaxis**
 - Ciprofloxacin for 60 days + Doxycycline for 60 days or Amoxicillin for 60 days (given if strain is penicillin sensitive).
- **Raxibacumab** - Monoclonal antibody that neutralizes anthrax toxin (protective antigen)
 - For prophylaxis & treatment of inhalational anthrax



Prevention

- **General control measures**
 - Disposal of animal carcasses by burning or by deep burial in lime pits
 - Decontamination (usually by autoclaving) of animal products
 - Protective clothing and gloves for handling potentially infectious materials.



Prevention - Immunoprophylaxis

- **Live Attenuated, Non-capsulated Spore Vaccine (Stern Vaccine)**
 - For animals. Protective for 1 year
 - Not safe for human use.
- **Adsorbed (Alum Precipitated) Toxoid Vaccine**
 - Prepared from the protective antigen
 - Safe & effective for human use
 - Indicated for pre exposure and post exposure prophylaxis



Anthrax Vaccines

Indication	Route	Dosing Schedule
Pre-exposure prophylaxis for persons at high risk of exposure	Intramuscular (0.5 mL/dose)	Primary series: 0,1, and 6 months Boosters: at 6 and 12 month after primary series and then yearly
Post-exposure prophylaxis following exposure to suspected or confirmed case	Subcutaneous (0.5 mL/dose)	0, 2, and 4 weeks postexposure combined with antimicrobial therapy

Anthrax bacilli v/s Anthracoid bacilli

	Anthrax bacilli	Anthracoid bacilli
Motility	Non motile	Motile
Capsule	Present	Absent
Bacilli	In long chain	In short chain
Under low power microscope	Medusa head colony seen	Not seen
Blood agar	No hemolysis	Hemolytic colony
Broth	Turbidity absent	Usually turbid

Anthrax bacilli v/s Anthracoid bacilli

	Anthrax bacilli	Anthracoid bacilli
Salicin	Not fermented	Fermented
Gamma phage	Susceptible	Resistant
Gelatin stab agar	Inverted fir tree appearance seen. Gelatin liquefaction slow	Not seen Rapid gelatin liquefaction
Solid medium with penicillin	String of pearls appearance	No growth
At 45°C	No growth	Usually grows
Virulence	Pathogenic	Mostly non-pathogenic



BACILLUS CEREUS



Bacillus cereus

- Normal habitant of soil
- Widely isolated from vegetables, milk, cereals, spices, meat & poultry
- **Food poisoning**
- Diarrheal toxin (causes diarrheal type of food poisoning)
- Emetic toxin (causes emetic type of food poisoning)
- **Ocular disease** - Severe keratitis & panophthalmitis following trauma to the eye

Bacillus cereus Food Poisoning

B.cereus	Diarrheal type	Emetic type
Incubation period	8-16 hours	1-5 hours
Toxin	Secreted in intestine (Similar to Clostridium perfringens enterotoxin)	Preformed toxin (formed in diet, similar to S.aureus enterotoxin)
	Heat labile	Heat stable
Food items contaminated	Meat, vegetables, dried beans, cereals	Rice (Chinese fried rice)
Clinical feature	Diarrhea, fever , rarely nausea	Vomiting, abdominal cramps
Serotype involved	2,6,8,9,10,12	1,3,5



Laboratory Diagnosis & Treatment

- **Sample** – feces
- ***Culture isolation***
 - **MYPA** (mannitol, egg yolk, polymyxin, phenol red and agar)
 - **PEMBA** (polymyxin B, egg yolk, mannitol, bromothymol blue, agar)
- Motile, non-capsulated & not susceptible to gamma phage



- **Treatment of *Bacillus cereus***

- Susceptible to clindamycin, erythromycin, vancomycin, aminoglycosides and tetracycline
- Resistant to penicillin (by producing β -lactamase) and trimethoprim



Bacillus spores as Biological controls

- **Geobacillus stearothermophilus**
 - Autoclave, H₂O₂ gas plasma sterilization & liquid acetic acid sterilizer
- **Bacillus atropheus**
 - Ethylene oxide sterilizer and dry heat sterilization